Workflow
大参林: 大参林医药集团股份有限公司2025年第一次临时股东大会会议材料

Core Viewpoint - The company is preparing for its upcoming shareholder meeting scheduled for June 25, 2025, focusing on the election of a new non-independent director and ensuring compliance with relevant laws and regulations [2][3][5]. Meeting Details - The meeting will be held at the company's headquarters in Guangzhou, with both on-site and online voting options available for shareholders [2][3]. - The meeting will commence at 10:30 AM, with specific time slots allocated for online voting [2]. Agenda and Procedures - The agenda includes signing in, announcing the number of shareholders present, selecting vote counters, and discussing various proposals [2][3][4]. - Shareholders will have the opportunity to speak and vote on the proposals, with specific rules governing the speaking time and number of times a shareholder can speak [3][5]. Proposal for Director Election - A key proposal involves the election of Mr. Ke Tuoki as a non-independent director, nominated by the controlling shareholder Mr. Ke Yunfeng [5][6]. - Mr. Ke Tuoki has no current shareholding in the company and is related to Mr. Ke Yunfeng as his son, which aligns with the company's nomination regulations [5][6]. Qualifications of the Nominee - The nomination committee has reviewed Mr. Ke Tuoki's qualifications and confirmed that he meets the necessary criteria to serve as a director [6]. - There are no legal restrictions preventing him from holding the position, and he is not listed as a market disqualified individual by the China Securities Regulatory Commission [6].